|
US645503A
(en)
|
1899-05-11 |
1900-03-13 |
Timothy Francis Crowley |
Cutter-gage for ice-cream, & c.
|
|
US953924A
(en)
|
1909-06-28 |
1910-04-05 |
Dow Wire & Iron Works |
Sliding door.
|
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
|
AU5154098A
(en)
|
1996-10-31 |
1998-05-22 |
Duke University |
Soluble tie2 receptor
|
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
|
ATE241380T1
(de)
|
1999-03-26 |
2003-06-15 |
Regeneron Pharma |
Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
EP1046715A1
(en)
|
1999-04-23 |
2000-10-25 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
|
|
US6897201B2
(en)
*
|
2000-08-21 |
2005-05-24 |
Inspire Pharmaceuticals, Inc. |
Compositions and methods for the treatment of glaucoma or ocular hypertension
|
|
WO2003034990A2
(en)
|
2001-10-25 |
2003-05-01 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
AU2003229627A1
(en)
|
2002-04-08 |
2003-10-20 |
Max-Planck-Gesellschaft Zur |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
|
JP2006501147A
(ja)
|
2002-04-25 |
2006-01-12 |
ユニバーシティー オブ コネティカット ヘルス センター |
非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
UA86053C2
(ru)
|
2004-03-15 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Соединения как модуляторы опиоидных рецепторов
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
SI1771474T1
(sl)
|
2004-07-20 |
2010-06-30 |
Genentech Inc |
Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
|
|
KR100980693B1
(ko)
|
2004-09-28 |
2010-09-07 |
(주) 에이프로젠 |
꼬인 코일형 키메라분자를 유효성분으로 하는 발기부전 치료제
|
|
US20080267971A1
(en)
|
2004-12-21 |
2008-10-30 |
Green Larry L |
Antibodies Directed to Angiopoietin-2 and Uses Thereof
|
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
TW200744567A
(en)
*
|
2005-09-23 |
2007-12-16 |
Alcon Inc |
Phenylethylamine analogs and their use for treating glaucoma
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
US20090123474A1
(en)
|
2005-12-15 |
2009-05-14 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
|
AU2007223796B2
(en)
|
2006-03-08 |
2013-01-24 |
Astellas Us Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
DE102006016426A1
(de)
|
2006-04-07 |
2007-10-11 |
Merck Patent Gmbh |
Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
|
|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint Pharmaceuticals, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
PT2076290T
(pt)
|
2006-10-27 |
2017-01-17 |
Sunnybrook Health Sciences Center |
Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
US9403789B2
(en)
|
2008-02-21 |
2016-08-02 |
Sequoia Pharmaceuticals, Inc. |
Benzofuran-containing amino acid inhibitors of cytochrome P450
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
SG172312A1
(en)
|
2009-01-12 |
2011-07-28 |
Akebia Therapeutics Inc |
Methods for treating vascular leak syndrome
|
|
WO2010097800A1
(en)
|
2009-02-26 |
2010-09-02 |
Muhammad Abdulrazik |
Synergistic combination of bioactive compounds for lowering of intraocular pressure
|
|
MX2011008731A
(es)
|
2009-03-03 |
2011-09-29 |
Alcon Res Ltd |
Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
|
|
BRPI1008920A2
(pt)
|
2009-03-03 |
2015-08-25 |
Alcon Res Ltd |
Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
CN105412094A
(zh)
|
2009-07-06 |
2016-03-23 |
爱尔皮奥治疗有限公司 |
用于防止癌细胞转移的化合物、组合物和方法
|
|
ES2877629T3
(es)
|
2010-07-12 |
2021-11-17 |
Immunogenesis Inc |
Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
NZ610230A
(en)
|
2010-10-07 |
2015-07-31 |
Aerpio Therapeutics Inc |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
WO2012073627A1
(ja)
|
2010-12-02 |
2012-06-07 |
丸善製薬株式会社 |
Ｔｉｅ２活性化剤、血管内皮増殖因子（ＶＥＧＦ）阻害剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物
|
|
CN107080843A
(zh)
|
2011-10-13 |
2017-08-22 |
爱尔皮奥治疗有限公司 |
眼病的治疗
|
|
US20130095065A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for Treating Vascular Leak Syndrome and Cancer
|
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
|
WO2013155512A2
(en)
|
2012-04-13 |
2013-10-17 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
|
PE20150361A1
(es)
|
2012-07-13 |
2015-03-14 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
|
|
JP6371765B2
(ja)
|
2012-07-31 |
2018-08-08 |
ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ |
糖尿病治療用医薬組成物
|
|
DK2906246T3
(da)
|
2012-10-11 |
2023-09-04 |
Ascendis Pharma Ophthalmology Div A/S |
VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
|
|
EA034963B1
(ru)
|
2012-11-08 |
2020-04-13 |
Клиасайд Байомедикал, Инк. |
Способ лечения расстройства заднего сегмента глаза
|
|
WO2014079709A1
(en)
|
2012-11-23 |
2014-05-30 |
Ab Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
HK1206558A1
(en)
*
|
2013-03-15 |
2016-01-15 |
Aerpio Therapeutics Inc |
Compositions, formulations and methods for treating ocular diseases
|
|
WO2014165963A1
(en)
|
2013-04-11 |
2014-10-16 |
Sunnybrook Research Institute |
Methods, uses and compositions of tie2 agonists
|
|
JP2016522249A
(ja)
|
2013-06-20 |
2016-07-28 |
ノバルティス アーゲー |
脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
US20160151410A1
(en)
|
2013-07-02 |
2016-06-02 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
|
US20160168240A1
(en)
|
2013-07-11 |
2016-06-16 |
Sergey AKSENOV |
Use of vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
RU2676303C2
(ru)
|
2013-07-11 |
2018-12-27 |
Новартис Аг |
Использование антагониста vegf для лечения ретролентальной фиброплазии
|
|
US9828422B2
(en)
|
2013-07-29 |
2017-11-28 |
Samsung Electronics Co., Ltd. |
Anti-Ang2 antibody
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
CN105765385B
(zh)
|
2013-10-01 |
2019-02-01 |
斯弗因高泰克有限公司 |
预测出现主要不良心脏事件的风险的方法
|
|
LT3062811T
(lt)
|
2013-11-01 |
2019-05-10 |
Regeneron Pharmaceuticals, Inc. |
Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui
|
|
EP3116503A4
(en)
*
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Hptp-beta inhibitors
|
|
WO2015152416A1
(ja)
*
|
2014-04-04 |
2015-10-08 |
国立大学法人東北大学 |
眼圧降下剤
|
|
WO2015152415A1
(ja)
|
2014-04-04 |
2015-10-08 |
株式会社ダイゾー |
吐出容器
|
|
US9719135B2
(en)
*
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
WO2016049183A1
(en)
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI738632B
(zh)
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
ES2981607T3
(es)
*
|
2015-09-23 |
2024-10-09 |
Eyepoint Pharmaceuticals Inc |
Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
|
|
AU2020264969B2
(en)
*
|
2019-04-29 |
2025-06-05 |
EyePoint Pharmaceuticals, Inc. |
Tie-2 activators targeting the schlemm's canal
|